Response to imatinib
| Response . | Patients with variant translocations (n = 30) . | Patients without variant translocations (n = 529) . | P . |
|---|---|---|---|
| CHR | |||
| Overall | 28 (93%) | 518 (98%) | .150 |
| CCgR | |||
| 12-month | 21 (70%) | 413 (78%) | .366 |
| Overall | 25 (83%) | 466 (88%) | .394 |
| MMolR | |||
| 12-month | 17 (57%) | 312 (59%) | .850 |
| Overall | 25 (83%) | 450 (85%) | .793 |
| Response . | Patients with variant translocations (n = 30) . | Patients without variant translocations (n = 529) . | P . |
|---|---|---|---|
| CHR | |||
| Overall | 28 (93%) | 518 (98%) | .150 |
| CCgR | |||
| 12-month | 21 (70%) | 413 (78%) | .366 |
| Overall | 25 (83%) | 466 (88%) | .394 |
| MMolR | |||
| 12-month | 17 (57%) | 312 (59%) | .850 |
| Overall | 25 (83%) | 450 (85%) | .793 |
Patients were categorized by their response at 12 months and by their best overall response.